|
15 Jul 2025 |
Healthcare Global
|
Consensus Share Price Target
|
566.30 |
567.29 |
- |
0.17 |
buy
|
|
|
|
|
28 Jun 2025
|
Healthcare Global
|
Axis Direct
|
566.30
|
600.00
|
544.80
(3.95%)
|
5.95 |
Buy
|
|
|
We recommend a BUY with TP of Rs 600, implying an upside of 10% from the CMP.
|
|
27 May 2025
|
Healthcare Global
|
Prabhudas Lilladhar
|
566.30
|
620.00
|
533.80
(6.09%)
|
9.48 |
Buy
|
|
|
HealthCare Global Enterprises' (HCG) Q4 consolidated EBITDA grew by 15% YoY to Rs1.1bn; in line with our estimate. The company's asset-light approach with a focus on partnerships has made its business model more capital efficient and scalable, in our view. We believe the strategic investment by KKR will bring in more operational and financial efficiency. Currently, HCG enjoys 13-14% pre IND AS margin, which is lower than its peers. We expect KKR to drive growth through bed expansion, rationalization of existing assets and scale up of...
|
|
27 May 2025
|
Healthcare Global
|
Axis Direct
|
566.30
|
620.00
|
533.80
(6.09%)
|
9.48 |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
21 Apr 2025
|
Healthcare Global
|
Geojit BNP Paribas
|
566.30
|
628.00
|
595.65
(-4.93%)
|
Target met |
Hold
|
|
|
|
|
28 Feb 2025
|
Healthcare Global
|
Prabhudas Lilladhar
|
566.30
|
555.00
|
501.65
(12.89%)
|
Target met |
Buy
|
|
|
With 51% stake in HCG, KKR has become the largest shareholder. We believe the strategic investment by KKR will bring in more operational and financial efficiency. Currently, HCG enjoys 15% pre IND AS margin, which is lower than its peers. We expect KKR to drive growth through bed expansion, rationalization of existing assets and scale up of margins. The company's asset-light approach with a focus on partnerships has made its business model more capital efficient and scalable, in our view. Our FY26/FY27E EBITDA stands...
|
|
28 Feb 2025
|
Healthcare Global
|
Axis Direct
|
566.30
|
575.00
|
501.65
(12.89%)
|
Target met |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
25 Feb 2025
|
Healthcare Global
|
ICICI Securities Limited
|
566.30
|
525.00
|
515.15
(9.93%)
|
Target met |
Hold
|
|
|
HealthCare Global Enterprises’ (HCG) current promoter CVC Capital (Aseco PTE) is likely to sell up to 54% of its stake in the company to another private equity (PE) firm, KKR, at an agreed price of INR 445/share (cumulative value between INR 320bn–339bn).
|
|
11 Dec 2024
|
Healthcare Global
|
Axis Direct
|
566.30
|
575.00
|
504.45
(12.26%)
|
Target met |
Buy
|
|
|
We recommend HCG with a BUY rating and a target price of Rs 575/share, implying a 14% upside from the CMP.
|
|
12 Nov 2024
|
Healthcare Global
|
Axis Direct
|
566.30
|
535.00
|
467.55
(21.12%)
|
Target met |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
12 Nov 2024
|
Healthcare Global
|
ICICI Direct
|
566.30
|
600.00
|
467.55
(21.12%)
|
Target met |
Buy
|
|
|
|
|
12 Aug 2024
|
Healthcare Global
|
ICICI Direct
|
566.30
|
455.00
|
356.05
(59.05%)
|
Target met |
Buy
|
|
|
|
|
12 Aug 2024
|
Healthcare Global
|
Prabhudas Lilladhar
|
566.30
|
420.00
|
356.05
(59.05%)
|
Target met |
Buy
|
|
|
|
|
09 Aug 2024
|
Healthcare Global
|
Axis Direct
|
566.30
|
395.00
|
362.25
(56.33%)
|
Target met |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
28 Jun 2024
|
Healthcare Global
|
Geojit BNP Paribas
|
566.30
|
407.00
|
380.00
(49.03%)
|
Target met |
Hold
|
|
|
|
|
31 May 2024
|
Healthcare Global
|
Axis Direct
|
566.30
|
400.00
|
360.75
(56.98%)
|
Target met |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
18 Mar 2024
|
Healthcare Global
|
ICICI Direct
|
566.30
|
435.00
|
342.80
(65.20%)
|
Target met |
Buy
|
|
|
|
|
12 Mar 2024
|
Healthcare Global
|
Geojit BNP Paribas
|
566.30
|
301.00
|
329.65
(71.79%)
|
|
Sell
|
|
|
|
|
12 Feb 2024
|
Healthcare Global
|
Axis Direct
|
566.30
|
410.00
|
360.30
(57.17%)
|
Target met |
Buy
|
|
|
Oncology is the fastest-growing industry in the healthcare market with a CAGR of 13.5% during FY22-FY27E. Recommendation: BUY
|
|
15 Nov 2023
|
Healthcare Global
|
Axis Direct
|
566.30
|
410.00
|
362.65
(56.16%)
|
Target met |
Buy
|
|
|
Oncology is the fastest-growing industry in the healthcare market with a CAGR of 13.5% during FY22-FY27E. We have BUY on the stock
|
|
18 Sep 2023
|
Healthcare Global
|
Geojit BNP Paribas
|
566.30
|
402.00
|
359.35
(57.59%)
|
Target met |
Accumulate
|
|
|
|